A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

REVEAL GENOMICS®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical ...

Women with high-risk HER2-positive breast cancer lived significantly ... "We know that patients who achieve a pathologic complete response [pCR] with neoadjuvant therapy do quite well and they ...

By RPS group, 9 of 18 (50%) (13 metapBC, 3 other, 2 lobular) in the HER2-Immune+ group who received RPS optimized therapy had a pCR. In this group 6/13 (46%) with metapBC had a pCR. In the HER2 ...